相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
Paul C. Cremer et al.
LANCET RHEUMATOLOGY (2021)
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Carlos Salama et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
I. O. Rosas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Anthony C. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
Ryan S. Thwaites et al.
SCIENCE IMMUNOLOGY (2021)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani et al.
LANCET (2021)
MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION
L. Pupim et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou et al.
NATURE MEDICINE (2021)
Alive and Ventilator Free: A Hierarchical, Composite Outcome for Clinical Trials in the Acute Respiratory Distress Syndrome*
Victor Novack et al.
CRITICAL CARE MEDICINE (2020)
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia
Mrinal M. Patnaik et al.
BLOOD (2020)
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
Yonggang Zhou et al.
NATIONAL SCIENCE REVIEW (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
Megan Melody et al.
IMMUNOTHERAPY (2020)
Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions
Matthijs Kox et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
Zelalem Temesgen et al.
MAYO CLINIC PROCEEDINGS (2020)
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
Giacomo De Luca et al.
LANCET RHEUMATOLOGY (2020)
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients
Yong Xiong et al.
EMERGING MICROBES & INFECTIONS (2020)
Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma
Nestor A. Molfino et al.
BMJ OPEN (2016)
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
Eric Padron et al.
BLOOD (2013)
Preclinical Characterization of KB003, a Novel Humaneered™ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML)
Eric Padron et al.
BLOOD (2012)
Adaptive increase in sample size when interim results are promising: A practical guide with examples
Cyrus R. Mehta et al.
STATISTICS IN MEDICINE (2011)
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Mohammad Tabrizi et al.
AAPS JOURNAL (2010)
分享论文
